Moderna-Merck Cancer Vaccine Shows Early Promise Against Melanoma Recurrence

A promising new cancer treatment has emerged from a collaboration between Moderna and Merck. The duo's personalised vaccine, combined with Keytruda, has shown encouraging results in reducing the risk of melanoma recurrence.

The experimental vaccine is tailored to each patient's unique tumour characteristics using genetic information from their tumour cells.

This approach trains immune cells to identify and attack cancer cells carrying specific tumour markers. The combination therapy is being evaluated alongside Keytruda, an established immunotherapy that helps the immune system target cancer by blocking a protein used by tumours to evade immune responses.

The early findings indicate that this combination performed better than Keytruda alone in reducing the likelihood of melanoma returning.